This Freiburg-based start-up wants to use a capital increase of EUR 16.3 million to bring its mini-lab for testing for corona viruses on to the market before the end of 2020.
41 Project proposals have made it through the first selection round and are now to receive funding for the conceptual phase.
Neurimmune and Ethris announce their exclusive partnership for developing immunotherapy. Clinical trials are set to start by the end of 2020.
Mainz-based biotech joins the race to develop a vaccine against coronavirus. Partnering with US pharmaceutical giant Pfizer for development and worldwide marketing.
Biotech secures new US partner: Recent merger with Canopy Biosciences followed by Core Diagnostics takeover.
High-quality peptide combinations made from alternative agricultural waste for healthy nutrition
Designer recombinases platform for precise genome surgery
Aminolipine for formaldehyde-free fixing of biological materials
Gene therapy to fight epilepsy
T-cell immunotherapy to fight blood cancers
New nano-sized carrier system for chemotherapeutics
Platform technology for highly parallel single-cell genetic analysis of tumour tissue
User data is collected from you whenever you visit this site. To find out how the Federal Ministry of Education and Research (BMBF) handles your data and the purpose of processing your data please refer to our statement on data protection.